FDA.reportPublic FDA data

0.8 ML adalimumab-aqvh 50 MG/ML Auto-Injector

RxCUI
2640397
RxNorm name
0.8 ML adalimumab-aqvh 50 MG/ML Auto-Injector
Display name
0.8 ML adalimumab-aqvh 50 MG/ML Auto-Injector
Full name
0.8 ML adalimumab-aqvh 50 MG/ML Auto-Injector
Term type
SCD
Status
DailyMed mapping
Updated
2026-06-04 23:39:21

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761216Yusimryadalimumab-aqvh351(k) BiosimilarRx2026-07-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
YUSIMRYADALIMUMAB-AQVHMeitheal Pharmaceuticals Inc.4cab600d-6950-409f-a6d8-d447da22cd952025-10-31Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2640397
YUSIMRYADALIMUMAB-AQVHCoherus BioSciences Inccd0e7af2-7704-49ce-bde9-f645294b67882025-05-16Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2640397

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 2 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
4cab600d-6950-409f-a6d8-d447da22cd95adalimumab-aqvh 40 MG in 0.8 ML Auto-Injector [PSN] · 0.8 ML adalimumab-aqvh 50 MG/ML Auto-Injector [SCD] · adalimumab-aqvh 40 MG per 0.8 ML Auto-Injector [SY]36These highlights do not include all the information needed to use YUSIMRY safely and effectively. See full prescribing information for YUSIMRY. YUSIMRY (adalimumab-aqvh) injection, for subcutaneous use Initial U.S. Approval: 2021 YUSIMRY (adalimumab-aqvh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee20251031
cd0e7af2-7704-49ce-bde9-f645294b6788adalimumab-aqvh 40 MG in 0.8 ML Auto-Injector [PSN] · 0.8 ML adalimumab-aqvh 50 MG/ML Auto-Injector [SCD] · adalimumab-aqvh 40 MG per 0.8 ML Auto-Injector [SY]36These highlights do not include all the information needed to use YUSIMRY safely and effectively. See full prescribing information for YUSIMRY. YUSIMRY (adalimumab-aqvh) injection, for subcutaneous use Initial U.S. Approval: 2021 YUSIMRY (adalimumab-aqvh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee20250516